Molecular Cardiology Research Laboratories, Vascular and Medicinal Research, The Texas Heart Institute, Houston, Texas, 77030, USA.
Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, Texas, 77030, USA.
Curr Atheroscler Rep. 2024 Jul;26(7):317-329. doi: 10.1007/s11883-024-01209-3. Epub 2024 May 16.
PURPOSE OF REVIEW: Low-density lipoprotein (LDL) poses a risk for atherosclerotic cardiovascular disease (ASCVD). As LDL comprises various subtypes differing in charge, density, and size, understanding their specific impact on ASCVD is crucial. Two highly atherogenic LDL subtypes-electronegative LDL (L5) and Lp(a)-induce vascular cell apoptosis and atherosclerotic changes independent of plasma cholesterol levels, and their mechanisms warrant further investigation. Here, we have compared the roles of L5 and Lp(a) in the development of ASCVD. RECENT FINDINGS: Lp(a) tends to accumulate in artery walls, promoting plaque formation and potentially triggering atherosclerosis progression through prothrombotic or antifibrinolytic effects. High Lp(a) levels correlate with calcific aortic stenosis and atherothrombosis risk. L5 can induce endothelial cell apoptosis and increase vascular permeability, inflammation, and atherogenesis, playing a key role in initiating atherosclerosis. Elevated L5 levels in certain high-risk populations may serve as a distinctive predictor of ASCVD. L5 and Lp(a) are both atherogenic lipoproteins contributing to ASCVD through distinct mechanisms. Lp(a) has garnered attention, but equal consideration should be given to L5.
目的综述:低密度脂蛋白(LDL)可导致动脉粥样硬化性心血管疾病(ASCVD)。由于 LDL 包含在电荷、密度和大小上有所不同的各种亚型,因此了解它们对 ASCVD 的具体影响至关重要。两种高度致动脉粥样硬化的 LDL 亚型——负电性 LDL(L5)和 Lp(a)——独立于血浆胆固醇水平诱导血管细胞凋亡和动脉粥样硬化变化,其机制值得进一步研究。在这里,我们比较了 L5 和 Lp(a) 在 ASCVD 发展中的作用。
最近的发现:Lp(a) 倾向于在动脉壁中积累,通过促血栓形成或抗纤维蛋白溶解作用促进斑块形成并可能引发动脉粥样硬化进展。高 Lp(a) 水平与钙化性主动脉狭窄和动脉粥样硬化血栓形成风险相关。L5 可诱导内皮细胞凋亡,增加血管通透性、炎症和动脉粥样硬化形成,在引发动脉粥样硬化中起关键作用。某些高危人群中升高的 L5 水平可能是 ASCVD 的一个独特预测因子。L5 和 Lp(a) 都是致动脉粥样硬化的脂蛋白,通过不同的机制导致 ASCVD。Lp(a) 引起了关注,但同样应考虑 L5。
Curr Atheroscler Rep. 2024-7
Cardiovasc Drugs Ther. 2019-12
Curr Opin Cardiol. 2024-11-1
Clin Res Cardiol Suppl. 2017-3
J Lipid Res. 2010-6-28
N Engl J Med. 2022-11-17
Curr Opin Lipidol. 2022-6-1
Nat Rev Immunol. 2022-5